Fisher Asset Management LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 9.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 214,045 shares of the biotechnology company’s stock after purchasing an additional 18,384 shares during the period. Fisher Asset Management LLC’s holdings in Exelixis were worth $12,502,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Eurizon Capital SGR S.p.A. acquired a new position in shares of Exelixis in the 3rd quarter valued at $357,000. Werba Rubin Papier Wealth Management acquired a new stake in Exelixis during the 3rd quarter worth about $213,000. CENTRAL TRUST Co lifted its position in Exelixis by 44.9% during the 3rd quarter. CENTRAL TRUST Co now owns 784 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 243 shares during the period. Maryland State Retirement & Pension System grew its stake in Exelixis by 15.6% during the 3rd quarter. Maryland State Retirement & Pension System now owns 15,157 shares of the biotechnology company’s stock valued at $885,000 after purchasing an additional 2,042 shares during the last quarter. Finally, New York Life Investment Management LLC grew its stake in Exelixis by 9.9% during the 3rd quarter. New York Life Investment Management LLC now owns 32,131 shares of the biotechnology company’s stock valued at $1,877,000 after purchasing an additional 2,886 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on EXEL shares. Zacks Research raised Exelixis from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 1st. Leerink Partners upped their target price on Exelixis from $55.00 to $58.00 and gave the company a “market perform” rating in a research report on Thursday, November 5th. Morgan Stanley cut their price target on shares of Exelixis from $60.00 to $57.00 and set an “equal weight” rating on the stock in a report on Friday. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research report on Monday, October 19th. Finally, Truist Financial lifted their price objective on shares of Exelixis from $54.00 to $60.00 and gave the company a “hold” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $58.62.
Read Our Latest Report on Exelixis
Exelixis Price Performance
Shares of NASDAQ EXEL opened at $69.00 on Monday. The business’s 50 day moving average is $62.29 and its two-hundred day moving average is $52.23. Exelixis, Inc. has a 52-week low of $39.71 and a 52-week high of $73.69. The firm has a market cap of $16.84 billion, a price-to-earnings ratio of 20.66, a PEG ratio of 1.78 and a beta of 0.45.
Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.89 by $0.05. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The business had revenue of $658.70 million during the quarter, compared to analyst estimates of $646.51 million. During the same period last year, the business posted $0.78 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Analysts anticipate that Exelixis, Inc. will post 3.42 EPS for the current fiscal year.
Exelixis Profile
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Further Reading
- Five stocks we like better than Exelixis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
